Warfarin versus aspirin: using CHADS2 to guide therapy for stroke prevention in nonvalvular atrial fibrillation

Area of Science:

• Cardiology
• Neurology
• Geriatrics

Background:

• Atrial fibrillation (AF) is a significant risk factor for ischemic stroke, particularly in elderly populations.
• Current guidelines recommend anticoagulation for stroke prevention in AF, with aspirin and warfarin as primary agents.
• The CHADS2 score stratifies cardioembolic stroke risk in AF patients.

Observation:

• Ischemic stroke incidence rises sharply with increasing CHADS2 scores, from 1.9 to 18.2 per 100 patient-years for scores 0 to 6.
• Warfarin demonstrates superior efficacy over aspirin in preventing AF-related strokes.
• Warfarin use is associated with a higher incidence of hemorrhagic events compared to aspirin.

Findings:

• The American College of Chest Physicians suggests warfarin for CHADS2 scores of 1 or higher, and recommends it for scores of 2 or more.
• A patient-specific approach is advocated, offering warfarin to individuals with a CHADS2 score of 1 or higher.
• Warfarin therapy should exclude patients at high risk for bleeding or those unable to undergo regular monitoring.

Implications:

• Personalized anticoagulation strategies are crucial for optimizing stroke prevention in AF.
• Balancing the benefits of warfarin against bleeding risks is essential for patient management.
• Further research may refine risk stratification and therapeutic recommendations for AF anticoagulation.